Chimeric Therapeutics (ASX:CHM) has moved to reassure investors of its strategic direction and clinical momentum, announcing a forthcoming refresh of its board and reaffirmed backing from major shareholders following its Annual General Meeting held on 25 November. …
Chimeric signals board refresh and shareholder support as lead trial advances
November 30, 2025 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 17 April
April 17, 2026 - - Podcast -
Australia, the US, and their different choices about health system trade-offs
April 17, 2026 - - Latest News -
Why hospitals, and not medicines, dominate America’s health spending gap
April 17, 2026 - - Latest News -
New strategic alliance for Biointelect aims to fast track life sciences innovation
April 17, 2026 - - Latest News -
Mark Butler confirms new and expanded cancer medicine listings
April 17, 2026 - - Latest News -
Why US health spending looks much higher than it really is
April 16, 2026 - - Latest News -
Pharmacy prescribing reform signals shift in NSW primary care with Victoria to follow
April 15, 2026 - - Latest News